Cholesterol, Total Test
The total cholesterol test measures the sum of cholesterol carried across all lipoprotein fractions, including LDL, VLDL, and HDL. Because it aggregates atherogenic and protective fractions, an elevated total cannot be interpreted for cardiovascular risk without the individual fractions, and treatment targets are set on LDL cholesterol and non-HDL cholesterol rather than total cholesterol.
1
Biomarkers
Blood (serum)
Sample
1–2 business days
Turnaround
No — total cholesterol is relatively stable non-fasting, though a fasting sample is preferred if a full lipid panel with triglycerides and calculated LDL-C may be added
Fasting
What is the Total Cholesterol test?
The Cholesterol, Total Test measures the sum of cholesterol carried across all lipoprotein fractions. It contributes to cardiovascular risk assessment and appears in risk-scoring algorithms, and is sometimes ordered as a simple screening measure or to track a single number over time. Within cardiovascular assessment, however, total cholesterol has limited standalone value and is not the preferred approach. Because it aggregates atherogenic LDL and VLDL with protective HDL, an elevated total cholesterol may reflect either increased cardiovascular risk or a favourable HDL, and the two cannot be distinguished without the fractions. Treatment decisions and targets rest on LDL cholesterol and non-HDL cholesterol, not on total cholesterol. For almost all clinical purposes the full lipid panel — total cholesterol, LDL-C, HDL-C, triglycerides, and the derived non-HDL-C — is preferred, and a standalone total cholesterol is best regarded as an incomplete assessment that usually warrants a full panel.
What does the Total Cholesterol test measure?
Total cholesterol represents the sum of cholesterol carried across all lipoprotein fractions, including LDL, HDL, and VLDL. Cholesterol is a sterol essential for cell membranes, steroid hormone synthesis, and bile acid production, derived from both hepatic synthesis and dietary intake. Because the measurement aggregates pro-atherogenic (LDL, VLDL) and protective (HDL) fractions into a single number, its clinical meaning depends entirely on how that cholesterol is distributed among the lipoproteins.
Total cholesterol is a long-standing component of cardiovascular risk assessment and contributes to risk-scoring algorithms, but on its own it is a coarse and potentially misleading measure: a raised total can reflect harmful LDL or protective HDL. It is most useful within the full lipid panel, where LDL-C, HDL-C, triglycerides, and non-HDL-C give it meaning, and it is not an adequate basis for treatment decisions in isolation.
Why is the Total Cholesterol test ordered?
- Basic cardiovascular risk screening where only a single cholesterol value is available or required, recognising the need for a full lipid panel to interpret it
- Contribution to cardiovascular risk-scoring algorithms that use total cholesterol alongside HDL and other risk factors
- Simple longitudinal tracking of a cholesterol trend in a patient already characterised by a full lipid panel
- Situations where a limited assessment is being performed and a full panel will follow if the total is abnormal
- Population or workplace screening contexts where a single measure is used as a trigger for fuller assessment
- Follow-up of a known dyslipidaemia where the treating practitioner is monitoring one component alongside prior full-panel results
- Assessment where an abnormal total cholesterol will prompt a full lipid panel, ApoB, or Lp(a) for proper characterisation
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
No — total cholesterol is relatively stable non-fasting, though a fasting sample is preferred if a full lipid panel with triglycerides and calculated LDL-C may be added
Collection method
Venipuncture at patient service centre
Turnaround
1–2 business days
Collection notes
Defer testing during acute illness or shortly after myocardial infarction. Document lipid-lowering and other relevant medications, thyroid status, and pregnancy. Consider ordering a full lipid panel, since total cholesterol alone cannot be interpreted for cardiovascular risk.
Specimen requirements
Minimum 0.5 mL serum. Separate serum from cells per Access Medical Laboratories protocol. Specimen stable refrigerated; follow Access Medical Laboratories transport guidelines.
What can affect Total Cholesterol results?
Total cholesterol sums LDL, VLDL, and HDL cholesterol, so a raised value can reflect harmful LDL or favourable HDL. Without the fractions the result cannot be interpreted for risk, which is the principal limitation of the standalone test.
Acute inflammatory states and the days to weeks following a myocardial infarction transiently lower cholesterol, so measurement should be deferred or interpreted with caution in these settings.
Cholesterol rises physiologically through pregnancy, so results are not interpreted against standard thresholds during gestation.
Lipid-lowering drugs reduce cholesterol, while oestrogens, corticosteroids, and retinoids can alter the lipid profile. Medication history should be documented.
Hypothyroidism raises cholesterol and hyperthyroidism lowers it, so thyroid status is relevant to interpreting an unexplained abnormality and is often checked in new dyslipidaemia.
Total cholesterol itself is relatively stable non-fasting, though the wider panel — particularly triglycerides and calculated LDL-C — is affected, which is another reason the full panel and its fasting requirements matter more than the total alone.
What do Total Cholesterol results mean?
Elevated
An elevated total cholesterol indicates increased circulating cholesterol but cannot, by itself, distinguish harmful LDL from protective HDL. It should prompt a full lipid panel to determine LDL-C, HDL-C, triglycerides, and non-HDL-C, which are what guide risk assessment and treatment.
Normal
A total cholesterol within the desirable range is reassuring but does not exclude an adverse lipid profile — for example, a normal total can mask a high LDL-C with a low HDL-C. The fractions are needed to assess risk properly.
Reduced
A low total cholesterol is generally favourable in the cardiovascular context and may reflect effective lipid-lowering therapy. Very low values can occasionally accompany acute illness, malnutrition, hyperthyroidism, or hepatic disease.
Note: Total cholesterol is a coarse measure with limited standalone value: it aggregates atherogenic and protective fractions and cannot guide treatment, since targets are set on LDL-C and non-HDL-C. A normal total can conceal an adverse distribution, and an elevated total can reflect a high HDL. In almost all clinical contexts the full lipid panel is preferred, and an abnormal or ambiguous standalone total should prompt one.
Frequently asked questions
It measures the sum of cholesterol carried across all lipoprotein fractions, including LDL, VLDL, and HDL. Because it aggregates atherogenic and protective fractions, it cannot be interpreted for risk on its own.
How to access the Total Cholesterol test
The Total Cholesterol reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: June 2, 2026
Last reviewed: June 2, 2026
- Grundy SM, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Circulation. (2019)
- Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. (2020)
- Nordestgaard BG, et al. Fasting is not routinely required for determination of a lipid profile. Eur Heart J. (2016)
- Boekholdt SM, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events. JAMA. (2012)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.
Related tests
cardiovascular
Lipid Panel
The standard lipid panel measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides, and derives non-HDL cholesterol, providing the core assessment of cardiovascular lipid risk. LDL-C is the principal treatment target and non-HDL-C an increasingly used secondary measure.
cardiovascular
Apo-B
The Apolipoprotein B (Apo-B) test counts the total number of atherogenic lipoprotein particles, since each LDL, VLDL, IDL, and lipoprotein(a) particle carries one apolipoprotein B. It is a strong cardiovascular risk marker, in many analyses superior to LDL cholesterol because it captures particle number rather than cholesterol content, and is especially informative where LDL cholesterol…
cardiovascular
Lp(a)
The lipoprotein(a) [Lp(a)] test measures a genetically determined, LDL-like particle that is an independent risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis. Because its level is largely inherited and stable through life, a single measurement usually suffices to establish lifelong risk.